Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab for Muscle Invasive Bladder Cancer
NCT00268450Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2005
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in bladder cancer, sponsored by Medical University of South Carolina. Started Sep 2005; status: terminated.
02
Drugs
bevacizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00268450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268450.